Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.
Identifieur interne : 000F75 ( PubMed/Corpus ); précédent : 000F74; suivant : 000F76Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.
Auteurs : Thomas Tesson ; Mathieu Blot ; Aurélie Fillion ; Hama Djerad ; Joséphine Cagnon-Chapalain ; Aline Creuwels ; Anne Waldner ; Michel Duong ; Marielle Buisson ; Sophie Mahy ; Pascal Chavanet ; Lionel PirothSource :
- Antiviral therapy [ 2040-2058 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (adverse effects), Anti-HIV Agents (therapeutic use), Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Drug Therapy, Combination, Female, HIV Infections (drug therapy), HIV Infections (immunology), HIV Infections (virology), Humans, Male, Middle Aged, Time Factors.
- MESH :
- chemical , adverse effects : Anti-HIV Agents.
- chemical , therapeutic use : Anti-HIV Agents.
- drug therapy : HIV Infections.
- immunology : HIV Infections.
- virology : HIV Infections.
- Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
First-line antiretroviral therapy (1st ART) is an important step in a patient's management and often considered a long-term therapy at treatment initiation.
DOI: 10.3851/IMP3084
PubMed: 27599563
Links to Exploration step
pubmed:27599563Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.</title><author><name sortKey="Tesson, Thomas" sort="Tesson, Thomas" uniqKey="Tesson T" first="Thomas" last="Tesson">Thomas Tesson</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Blot, Mathieu" sort="Blot, Mathieu" uniqKey="Blot M" first="Mathieu" last="Blot">Mathieu Blot</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fillion, Aurelie" sort="Fillion, Aurelie" uniqKey="Fillion A" first="Aurélie" last="Fillion">Aurélie Fillion</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, CH de Chalon sur Saône, Chalon sur Saône, France.</nlm:affiliation></affiliation></author><author><name sortKey="Djerad, Hama" sort="Djerad, Hama" uniqKey="Djerad H" first="Hama" last="Djerad">Hama Djerad</name><affiliation><nlm:affiliation>Service de Médecine Interne, CH de Nevers, Nevers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cagnon Chapalain, Josephine" sort="Cagnon Chapalain, Josephine" uniqKey="Cagnon Chapalain J" first="Joséphine" last="Cagnon-Chapalain">Joséphine Cagnon-Chapalain</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, CH de Macon, Macon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Creuwels, Aline" sort="Creuwels, Aline" uniqKey="Creuwels A" first="Aline" last="Creuwels">Aline Creuwels</name><affiliation><nlm:affiliation>Service de Médecine Interne, CH de Sens, Sens, France.</nlm:affiliation></affiliation></author><author><name sortKey="Waldner, Anne" sort="Waldner, Anne" uniqKey="Waldner A" first="Anne" last="Waldner">Anne Waldner</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Duong, Michel" sort="Duong, Michel" uniqKey="Duong M" first="Michel" last="Duong">Michel Duong</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Buisson, Marielle" sort="Buisson, Marielle" uniqKey="Buisson M" first="Marielle" last="Buisson">Marielle Buisson</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mahy, Sophie" sort="Mahy, Sophie" uniqKey="Mahy S" first="Sophie" last="Mahy">Sophie Mahy</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chavanet, Pascal" sort="Chavanet, Pascal" uniqKey="Chavanet P" first="Pascal" last="Chavanet">Pascal Chavanet</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Piroth, Lionel" sort="Piroth, Lionel" uniqKey="Piroth L" first="Lionel" last="Piroth">Lionel Piroth</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27599563</idno><idno type="pmid">27599563</idno><idno type="doi">10.3851/IMP3084</idno><idno type="wicri:Area/PubMed/Corpus">000F75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.</title><author><name sortKey="Tesson, Thomas" sort="Tesson, Thomas" uniqKey="Tesson T" first="Thomas" last="Tesson">Thomas Tesson</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Blot, Mathieu" sort="Blot, Mathieu" uniqKey="Blot M" first="Mathieu" last="Blot">Mathieu Blot</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fillion, Aurelie" sort="Fillion, Aurelie" uniqKey="Fillion A" first="Aurélie" last="Fillion">Aurélie Fillion</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, CH de Chalon sur Saône, Chalon sur Saône, France.</nlm:affiliation></affiliation></author><author><name sortKey="Djerad, Hama" sort="Djerad, Hama" uniqKey="Djerad H" first="Hama" last="Djerad">Hama Djerad</name><affiliation><nlm:affiliation>Service de Médecine Interne, CH de Nevers, Nevers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cagnon Chapalain, Josephine" sort="Cagnon Chapalain, Josephine" uniqKey="Cagnon Chapalain J" first="Joséphine" last="Cagnon-Chapalain">Joséphine Cagnon-Chapalain</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, CH de Macon, Macon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Creuwels, Aline" sort="Creuwels, Aline" uniqKey="Creuwels A" first="Aline" last="Creuwels">Aline Creuwels</name><affiliation><nlm:affiliation>Service de Médecine Interne, CH de Sens, Sens, France.</nlm:affiliation></affiliation></author><author><name sortKey="Waldner, Anne" sort="Waldner, Anne" uniqKey="Waldner A" first="Anne" last="Waldner">Anne Waldner</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Duong, Michel" sort="Duong, Michel" uniqKey="Duong M" first="Michel" last="Duong">Michel Duong</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Buisson, Marielle" sort="Buisson, Marielle" uniqKey="Buisson M" first="Marielle" last="Buisson">Marielle Buisson</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mahy, Sophie" sort="Mahy, Sophie" uniqKey="Mahy S" first="Sophie" last="Mahy">Sophie Mahy</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chavanet, Pascal" sort="Chavanet, Pascal" uniqKey="Chavanet P" first="Pascal" last="Chavanet">Pascal Chavanet</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Piroth, Lionel" sort="Piroth, Lionel" uniqKey="Piroth L" first="Lionel" last="Piroth">Lionel Piroth</name><affiliation><nlm:affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Antiviral therapy</title><idno type="eISSN">2040-2058</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (adverse effects)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Antiretroviral Therapy, Highly Active</term><term>CD4 Lymphocyte Count</term><term>Drug Therapy, Combination</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Antiretroviral Therapy, Highly Active</term><term>CD4 Lymphocyte Count</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">First-line antiretroviral therapy (1st ART) is an important step in a patient's management and often considered a long-term therapy at treatment initiation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27599563</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-2058</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.</ArticleTitle><Pagination><MedlinePgn>715-724</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP3084</ELocationID><Abstract><AbstractText Label="BACKGROUND">First-line antiretroviral therapy (1st ART) is an important step in a patient's management and often considered a long-term therapy at treatment initiation.</AbstractText><AbstractText Label="METHODS">To describe the duration of 1st ART and the factors associated with treatment modification in a recent real-life setting, antiretroviral-naive patients who began their 1st ART in six French hospitals in 2009-2012 were included in a cohort. Clinical, immunological, virological and therapeutic data, as well as the reasons for therapeutic changes, if any, were retrospectively collected.</AbstractText><AbstractText Label="RESULTS">A total of 206 patients started 1st ART, mainly a protease inhibitor-based triple therapy (73%), with a tenofovir-including backbone (87%). Of these, 89 (43%) had their 1st ART modified after a median of 16.5 months (IQR 8.0-32.8). Having a CD4<sup>+</sup> T-cell count <200 cells/mm<sup>3</sup>, being pregnant, or 1st ART including zidovudine + lamivudine or lopinavir/r were significantly associated with a higher risk for treatment modification in multivariate analysis. In 47 patients (53%), 1st ART was modified for safety reasons, with no significant association with a given antiretroviral drug or class. No significant difference in virological, immunological and clinical outcomes was observed between the patients who had their 1st ART modified and those who did not.</AbstractText><AbstractText Label="CONCLUSIONS">The proportion of modifications of the 1st ART during the first 2 years remains high. These modifications are frequently because of safety issues and the willingness to simplify treatment, and less often driven by virological failure, thus emphasizing that 1st ART is not - or is no longer - a lifelong treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tesson</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blot</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fillion</LastName><ForeName>Aurélie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses, CH de Chalon sur Saône, Chalon sur Saône, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djerad</LastName><ForeName>Hama</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, CH de Nevers, Nevers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cagnon-Chapalain</LastName><ForeName>Joséphine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses, CH de Macon, Macon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creuwels</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, CH de Sens, Sens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldner</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buisson</LastName><ForeName>Marielle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahy</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavanet</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MERS UMR1347, University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piroth</LastName><ForeName>Lionel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MERS UMR1347, University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Corresponding author e-mail: lionel.piroth@chu-dijon.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27599563</ArticleId><ArticleId IdType="doi">10.3851/IMP3084</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27599563
|texte= Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27599563" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |